- Open Access
Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes
Acta Neuropathologica Communications volume 8, Article number: 61 (2020)
The co-existence of multiple pathologies and proteins is a common feature in the brains of cognitively impaired elderly individuals. Transactive response DNA-binding protein (TDP-43) has been discovered to accumulate in limbic brain regions of a portion of late-onset Alzheimer’s disease (AD) patients, in addition to amyloid-β and τ protein. However, it is not yet known whether the TDP-43 species in the AD brain differ in their composition, when compared among different AD cases and to frontotemporal lobar degeneration cases with TDP-43 inclusions (FTLD-TDP). Furthermore, it is not known whether TDP-43 pathology in AD is related to symptoms of the frontotemporal dementia (FTD) spectrum. In this study, we investigated the molecular pattern of TDP-43 lesions with five different antibodies against different phosphorylated (pTDP-43) and non-phosphorylated TDP-43 epitopes. We analyzed a cohort of 97 autopsy cases, including brains from 20 non-demented individuals, 16 cognitively normal pathologically-defined preclinical AD (p-preAD), 51 neuropathologically-confirmed AD cases and 10 FTLD-TDP cases as positive controls. We observed distinct neuropathological patterns of TDP-43 among AD cases. In 11 neuropathologically-confirmed AD cases we found dystrophic neurites (DNs), neuronal cytoplasmic inclusions (NCIs) and/or neurofibrillary tangle (NFT)-like lesions not only positive for pTDP-43409/410, but also for pTDP-43 phosphorylated at serines 403/404 (pTDP-43403/404) and non-phosphorylated, full-length TDP-43, as seen with antibodies against C-terminal TDP-43 and N-terminal TDP-43. These cases were referred to as ADTDP + FL because full-length TDP-43 was presumably present in the aggregates. FTLD-TDP cases showed a similar molecular TDP-43 pattern. A second pattern, which was not seen in FTLD-TDP, was observed in most of p-preAD, as well as 30 neuropathologically-confirmed AD cases, which mainly exhibited NFTs and NCIs stained with antibodies against TDP-43 phosphorylated at serines 409/410 (pTDP-43409, pTDP-43409/410). Because only phosphorylated C-terminal species of TDP-43 could be detected in the lesions we designated these AD cases as ADTDP + CTF. Ten AD cases did not contain any TDP-43 pathology and were referred to as ADTDP-. The different TDP-43 patterns were associated with clinically typical AD symptoms in 80% of ADTDP + CTF cases, 63,6% of ADTDP + FL and 100% of the ADTDP- cases. On the other hand, clinical symptoms characteristic for FTD were observed in 36,4% of ADTDP + FL, in 16,6% of the ADTDP + CTF, and in none of the ADTDP- cases. Our findings provide evidence that TDP-43 aggregates occurring in AD cases vary in their composition, suggesting the distinction of different molecular patterns of TDP-43 pathology ranging from ADTDP- to ADTDP + CTF and ADTDP + FL with possible impact on their clinical picture, i.e. a higher chance for FTD-like symptoms in ADTDP + FL cases.
Alzheimer’s Disease (AD) is a progressive, neurodegenerative disorder and constitutes the most common form of dementia in people over 65 years of age . AD is characterized by two main neuropathological hallmarks: extracellular amyloid-β (Aβ) deposition in senile plaques and intracellular generation of neurofibrillary tangles (NFTs), neuropil threads, and neuritic plaques containing abnormally phosphorylated τ protein (p- τ) . Transactive response DNA-binding protein (TDP-43)-positive cytoplasmic inclusions in limbic areas occur in AD brains as well. They are present in up to 74% of AD cases [1, 2, 33, 40].
TDP-43 pathology has been described to expand in the AD brain in a stereotypical manner, starting in the amygdala and progressing into the medial temporal lobe and later into further regions such as temporal and frontal cortices [27, 47]. Furthermore, TDP-43 pathology in AD has been associated with a later onset of the disease, memory loss and hippocampal atrophy, playing a role in the clinical manifestation of the disease [28, 29]. Similar lesions have also been described in non-AD cases [40, 62].
Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) is a neurodegenerative disorder typically manifesting with behavioral changes or signs of aphasia , i.e., symptoms of the frontotemporal dementia (FTD) spectrum. Brettschneider et al. suggested that TDP-43 pathology spreads in a stereotypical manner in the behavioral variant of FTLD-TDP, with the prefrontal neocortex, middle-frontal gyrus, superior and middle-temporal gyri being heavily involved and with the amygdala being involved early in the disease . FTLD-TDP has been classified into different subtypes, according to the morphology and topographic distribution of TDP-43 lesions in the cortex .
TDP-43-positive inclusions in limbic brain regions have been recently considered as limbic-predominant age-associated TDP-43 encephalopathy-related neuropathological changes (LATE-NC) . This means that late-onset AD cases that have TDP-43 pathology may present concomitant LATE-NC, even without the clinical manifestation of LATE, according to the recent consensus working group report . LATE-NC has recently been established as TDP-43 neuropathology in individuals without amyotrophic lateral sclerosis (ALS) or FTLD, which can be found in elderly individuals (mostly 80 years of age or older) with and without AD .
A controversial point raised by recent studies is whether TDP-43 deposition in AD cases represents the co-existence of AD and FTLD-TDP, or whether TDP-43 proteinopathy in AD is substantially different from that of FTLD-TDP [25,26,27, 49]. Given the recently developed, controversial concept of LATE-NC encompassing TDP-43 lesions in AD, non-AD and non-demented patients, the question whether TDP-43 pathology in these cases displays distinct molecular signatures is even more relevant. Furthermore, it was not yet addressed whether such patterns are different from that observed in FTLD-TDP .
TDP-43 is a nuclear protein that under pathological conditions can be cleaved and phosphorylated . Due to the loss of the nuclear localization signal after cleavage, N-terminal truncated fragments of TDP-43 mislocalize and aggregate in the cytoplasm. In turn, the nucleus is depleted from normal TDP-43. Hence, a gain of toxic function in the cytoplasm as well as a loss of nuclear function seem to constitute TDP-43 disease mechanisms [50, 51]. Phosphorylation at serines 403/404 and 409/410 of TDP-43 constitutes pathological features of ALS and FTLD-TDP [2, 5, 18, 23, 48, 50]. However, the pattern of TDP-43 phosphorylation and species distribution present in AD cases is not yet understood.
Hence, we studied 97 autopsy cases including 20 non-AD/non-FTLD-TDP cases as controls, 16 pre-clinical AD cases, 51 neuropathologically-confirmed AD cases and 10 FTLD-TDP cases (used as positive controls). We screened our cohort with five different antibodies against several phosphorylated and non-phosphorylated TDP-43 epitopes. We report distinct molecular patterns of TDP-43 pathology among the cases with AD neuropathology based upon the detection of full-length TDP-43 or phosphorylated TDP-43 C-terminal fragments. These molecular differences were associated with a clinical presentation of AD or FTD symptoms.
Material and methods
A total of 97 autopsy cases between 36 and 98 years of age (mean age: 72 years old, 45 females and 52 males) were investigated: 20 non-diseased controls, 16 pre-clinical AD, 51 neuropathologically-confirmed AD cases and 10 FTLD-TDP cases as positive controls for TDP-43 pathology (Table 1, Additional file 1-Table A1). Cases with hippocampal sclerosis were not included, since this pathology is considered as separate entity or separate type of LATE [1, 47, 54]. All autopsy brains were received from university or municipal hospitals in Leuven (Belgium), Bonn, Offenbach am Main and Ulm (Germany), and collected in accordance with local ethical committee guidelines and the federal laws governing the use of human tissue for research in Belgium and Germany. Dementia was diagnosed according to the DSM-IV criteria. The neuropathological diagnosis of AD was made when dementia was observed and when at least an intermediate degree of AD-related neuropathology was determined according to current criteria for the neuropathological diagnosis of AD as published by the National Institute of Aging and Alzheimer Association working group (NIA-AA criteria) . The degree of dementia at the time of death was determined retrospectively using the Clinical Dementia Rating (CDR) score [19, 43]. For this purpose, the information from the clinical files was used to provide a CDR score. The CDR score was applied in controls and AD cases with AD clinical symptoms , whereas CDR with FTLD modules was used when scoring cases with a clinical picture of FTD . The diagnosis of FTD behavioral variant and of primary progressive aphasia variants FTLD was made using consensus criteria [16, 53].
The left hemispheres were fixed in formalin for 2 to 4 weeks and dissected. Blocks from frontal, parietal, temporal, occipital, and entorhinal cortex, the hippocampal formation at the level of the lateral geniculate body, basal ganglia, hypothalamus, thalamus, amygdala, basal nucleus of Meynert (NBM), midbrain, pons, medulla oblongata and cerebellum were embedded in paraffin. Five μm sections were cut using a microtome. The sections were stained with hematoxylin and eosin (H&E) for identification of pathologies different from AD and FTLD-related lesions.
Sections of the hippocampus, entorhinal, frontal, temporal and occipital cortex, amygdala, and NBM were stained with antibodies against TDP-43. Briefly, after epitope retrieval in heated citrate buffer (pH 6) and deparaffinization (using a Dako autostainer Link 48, Dako, Glostrup, Denmark), the sections were treated with peroxidase blocking reagent (Envision flex Peroxidase-Blocking Reagent, Dako) for 5 min. Primary antibodies (Additional file 1-Table A2) were applied for 30 min or overnight. The antibodies against TDP-43 provide the ability to detect specific sites of TDP-43 protein as well as the phosphorylation status at serines 403/404 and 409/410 (Fig. 1). Afterwards, the slides were incubated with an appropriate secondary antibody (Envision Dual flex, Dako). 3.3′-diaminobenzidine (Liquid DAB+ Substrate Chromogen System, Dako) was used as a chromogen to yield brown reaction products. Counterstaining with hematoxylin was performed. In sections of the hippocampus, entorhinal, temporal and occipital cortex, Aβ and p-τ immunostaining was performed using a similar protocol as described above, but with formic acid pre-treatment for antigen retrieval prior to the immunostaining procedure.
For immunofluorescence procedures, paraffin sections were incubated overnight with a cocktail of antibodies of different species (mouse TDP-43 C-terminus, rabbit TDP-43 N-terminus) (Additional file 1- Table A2) after the respective pre-treatment and deparaffinization. The sections were then incubated with a goat Cy2-labelled anti-mouse and goat Cy3-labelled anti-rabbit antibody cocktail (Jackson ImmunoResearch Ltd., West Grove, PA, USA) and mounted with ProLong™ Gold with DAPI (ThermoFisher Scientific, Rockford, IL, USA). The sections were microscopically analyzed with a Leica DM2000 LED microscope and images were taken with a Leica DFC7000 T camera, at 200 or 400x magnification.
The extent of p-τ, Aβ and TDP-43 pathology was assessed with antibodies against p-τ, Aβ and TDP-43 (Additional file 1-Table A2).
TDP-43 pathology analysis
A case was considered as TDP-43-positive in a given brain region, if there was TDP-43 immunoreactivity for one or more of the following lesions: neuronal cytoplasmic inclusions (NCIs), dystrophic neurites (DNs) or neuronal intranuclear inclusions (NIIs) (Fig. 2). Glial inclusions were not separately assessed, since none of our cases showed glial inclusions without associated neuronal TDP-43 pathology. Of note, a case was only considered to be TDP-43 negative when no TDP-43-positive lesion of any type, including glial inclusions, was detected. The identification of TDP-43 pathology was based on stainings with antibodies raised against pTDP-43409/410. pTDP-43409/410 staining in granulovacuolar degeneration (GVD) was not considered as a relevant TDP-43 lesion in this study, because it contains other phosphorylated proteins, such as compounds of the necrosome [35, 65] and it is not associated with nuclear clearance of TDP-43 . NCIs, DNs and NIIs positive for TDP-43 have been previously associated with ALS and FTLD-TDP, as well as with AD [1, 18, 29, 48, 58, 66]. pTDP-43 pathology was analyzed for the relevant phosphorylation sites with antibodies against pTDP-43409/410, pTDP-43409 and pTDP-43403/404 (Additional file 1-Table A2). For confirmation, a monoclonal rat (clone 1D3) antibody against pTDP-43409/410 was used. The non-phosphorylated TDP-43 C-terminus (C-t TDP-43) was stained with a rabbit polyclonal antibody raised against the non-phosphorylated amino acids 260–414 of TDP-43 and confirmed with a rabbit polyclonal antibody against the non-phosphorylated amino acids 405–414 (Additional file 1-Table A2). The N–terminus of TDP-43 (N-t TDP-43) was detected with a rabbit polyclonal antibody raised against the amino acids 1–50 (Fig. 1).
TDP-43 pathology types α and β as defined by Josephs et al. were determined in non-FTLD-TDP/non-ALS cases, as proposed , by using sections stained with anti-pTDP-43409/410 antibodies. The presence of DNs and NCIs in the amygdala, hippocampal formation, and the frontotemporal cortex were classified as type α whereas cases with NFT-like pathology restricted to limbic regions (amygdala and hippocampus) were classified as type β. In the event that cases exhibiting a type α distribution pattern also presented NFT-like TDP-43 pathology, we considered them as type α + β (Additional file 1- Table A1). This classification was applied by two independent observers (ST and EVS) with an 85,3% agreement rate. Adjustment for discrepancies was reduced in a consensus diagnosis after discussing the results together at the microscope. AD cases with widespread lesions in the temporal or frontal cortex and FTLD-TDP cases were subtyped into the known FTLD-TDP subtypes (A-D), as defined by Mackenzie et al. , by analyzing the morphology and topography of DNs and NCIs in temporal and frontal cortices (see Additional file 1-Table A1). If a case did not fit into any of these subtypes, as it presented large NCIs, scattered among all layers of the temporal cortex, little DNs and occasionally NFT-like lesions, it was not further classified (indicated by * in Additional file 1-Table A1). AD cases without TDP-43 pathology in cortical layers were also not further classified into an FTLD-TDP subtype A-D, as this classification requires TDP-43 pathology in cortical layers. For the assessment of LATE-NC pathology, cases with more than 80 years of age and TDP-43 pathology in limbic regions (amygdala and hippocampal formation) without exclusive FTD-related symptoms were considered to be positive . Cases younger than 80 years of age but older than 60 years with severe TDP-43 pathology restricted to limbic regions were also considered to represent LATE-NC. The amygdala, hippocampal formation and frontal cortex were used to stage for LATE-NC as proposed: Stage 0 = no LATE-NC; stage 1 = TDP-43 pathology restricted to the amygdala; stage 2 = TDP-43 pathology in the amygdala and hippocampal formation; stage 3 = TDP-43 pathology extending to the frontal cortex, in addition to stage 2 regions. LATE-NC staging was based on sections stained with a polyclonal antibody against pTDP-43 (pS409/pS410, Cosmobio). These criteria were not applied to the FTLD-TDP cases (positive controls). Of note, none of our cases fulfilled the criteria for hippocampal sclerosis according to the consensus criteria . Genetic mutations (i.e. C9ORF72) in some cases are also referred in Additional file 1-Table A1.
Aβ and τ pathology assessment
To determine the anatomical distribution of Aβ plaques, phases of Aβ deposition in the medial temporal lobe (AβMTL phases) were assessed as follows: Aβ plaques in the temporal neocortex (layers III, V and VI) characterize AβMTL phase 1. In AβMTL phase 2, the plaque deposition spreads into the layers pre-β – pri-γ of the entorhinal cortex, CA1, and the subiculum. AβMTL phase 3 is characterized by Aβ deposition in all six layers of the temporal neocortex including subpial band-like Aβ accumulation. In addition, Aβ plaques also occur in the outer molecular layer of the dentate gyrus and the parvopyramidal cell layer of the presubicular region. Finally, in AβMTL phase 4 there is fully developed β-amyloidosis in the medial temporal lobe with additional Aβ plaques in the CA4 region of the hippocampus and in the pre-α layer of the entorhinal cortex .
NFT distribution was assessed using the Braak NFT-staging method: Stage I is characterized by p-τ-positive neurons and threads, limited to the transentorhinal region, stage II by p-τ pathology in the entorhinal region, extending to CA1 and CA2, stage III by affection of the neocortex of the fusiform and lingual gyri, stage IV by progression into superior temporal neocortex areas and the dentate gyrus, stage V by the involvement of frontal and occipital cortex, reaching the peristriate region (layer V also begins to be affected) and finally, stage VI is identified by p-τ pathology in secondary and primary neocortical areas and extends into striate area of the occipital lobe [6, 7]. The consortium to establish a registry for AD (CERAD) scores for neuritic plaque density were assessed based on sections stained with an antibody against p-τ (AT8, Additional file 1-Tab. A1) . The National Institute of Aging - Alzheimer Association (NIA-AA) degree of AD-pathology was determined according to Hyman et al. , based on the AβMTL phase, Braak NFT-stage, and the CERAD score for neuritic plaque pathology. CAA was diagnosed whenever Aβ deposits were found in the wall of cerebral and leptomeningeal blood vessels . NFT pathology in the absence of Aβ plaque pathology was classified as definite primary age-related tauopathy (PART) .
Non-parametric, Kruskal-Wallis H-test was used for independent samples, to perform comparisons between disease groups (Braak NFT-stage, AβMTL phase, NIA-AA, Age at death, CDR score). Friedman test for related samples was used to compare different antibodies within the same disease group. Bonferroni correction for multiple testing was applied. Post-hoc power analysis was calculated based on mean values with the help of G-power software (University of Düsseldorf, Germany).
Binary logistic regression was used to assess associations between the molecular TDP-43 patterns found in this study with clinical symptoms, AD-related neuropathological changes (Braak NFT-stages and AβMTL phases) and to associate these patterns with the morphological subtypes defined by Josephs et al. . These analyses were controlled for age at death and sex, with a 95% confidence interval (CI).
Multinomial regression controlled for age and sex was used to further confirm the results obtained by Kruskal-Wallis H-test. For these regressions we used the symptomatic AD group as reference group.
IBM SPSS software (IBM, USA) was used in all instances.
Here, we analyzed the biological patterns of TDP-43 proteinopathy in demented cases with moderate-high degrees of AD pathology, pathologically defined pre-clinical AD (p-preAD) cases , FTLD-TDP cases and control cases (non-AD), by screening the whole cohort with five different TDP-43 antibodies. We distinguished distinct molecular patterns of TDP-43 pathology based on the different TDP-43 species and on the pattern of TDP-43 phosphorylation sites. Ten AD cases showed no TDP-43 pathology and were referred to as ADTDP- cases. Thirty AD cases were positive for NCIs and NFT-like lesions stained with antibodies raised against pTDP-43409/410, as well as pTDP-43409, but neither with anti-pTDP-43403/404 nor with antibodies against C- or N-terminus epitopes of TDP-43. This subgroup of AD cases was designated as ADTDP + CTF. Of note, there was one exceptional AD case with predominant pTDP-43409/410 epitope expression that also had very sparse N-t TDP-43 pathology in amygdala and temporal cortex, but no pTDP403/404-positive lesions. For this reason, we classified this case also as an ADTDP+CTF case. The remaining 11 neuropathologically-confirmed AD cases were positive not only for anti-pTDP43409/410 or anti-pTDP43409, but also for anti-pTDP-43403/404 and antibodies raised against non-phosphorylated TDP-43 species, such as C-t TDP-43 and N-t TDP-43. FTLD-TDP cases showed a similar expression pattern of these TDP-43 epitopes. Given the similarity of the TDP-43 staining pattern with the predominant expression of full-length TDP-43, the AD cases exhibiting all types of TDP-43 species were referred to as ADTDP + FL. Furthermore, 7 out of these 11 ADTDP + FL cases presented a morphological pattern of TDP-43 pathology compatible with one of the FTLD-TDP subtypes A-C as described before , whereas the remaining four cases did not fit into any of these subtypes (Additional file 1-Table A1).
Clinically, most ADTDP + CTF cases exhibited a typical AD phenotype during life (80%) and 13,3% presented primary progressive aphasia (PPA), whereas the ADTDP + FL cases showed variable clinical phenotypes with AD (63,6%) and/or FTD-related symptoms (36,4%), such as behavioral problems and personality changes (Table 2).
Distinct patterns of TDP-43 and its modified forms in cases fulfilling the neuropathological criteria for AD
To clarify the biological differences between TDP-43 patterns in AD cases, we investigated the prevalence of pTDP-43 and non-phosphorylated TDP-43 species. For that, we used phospho-dependent and phospho-independent antibodies against the N- and C-t epitopes of TDP-43 (Fig. 1). To test whether the TDP-43 staining patterns are consistent among different brain regions we analyzed hippocampal sub-regions (dentate gyrus, CA4, CA3/2, CA1, subiculum), amygdala, basal nucleus of Meynert (NBM), entorhinal, temporal, frontal and occipital cortices.
The number of positive cases for pTDP409 and pTDP409/410 in most regions analyzed in this study were similar among ADTDP + CTF and ADTDP + FL, with the exception of dentate gyrus, CA4, frontal and occipital cortex for pTDP409/410 and dentate gyrus, occipital cortex for pTDP409. This was due to the low abundance of TDP-43 pathology in ADTDP + CTF cases in these regions (Fig. 3 a-c, 4 Additional file 1- Fig. A1-A3, Tab. A3, 4). In turn, the predominance of TDP-43403/404 pathology in ADTDP + FL cases compared to ADTDP + CTF cases was higher in all regions analyzed except NBM and occipital cortex, which exhibited low pTDP-43403/404 pathology in both groups (Fig. 4, Additional file 1-Fig. A1-A3, A5). Furthermore, ADTDP + FL cases displayed a higher percentage of cases positive for non-phosphorylated TDP-43 in all regions except NBM compared to ADTDP + CTF cases, as seen with antibodies raised against the C-t TDP-43 (Fig. 4 a-c, Additional file 1-Fig. A3, A6). This was also true for the N-t-TDP-43 in all regions but CA4, CA3/2 and NBM (Fig. 4 a-c, Additional file 1-Fig. A3, A7).
Importantly, the differences between ADTDP + CTF and ADTDP + FL cases were analogous to those observed between ADTDP + CTF and FTLD-TDP cases (Fig. 3 a-c, Additional file 1-Fig. A1-A3). To indicate the power of our findings, we performed a post-hoc power analysis regarding the analysis of the five different TDP-43 markers in the CA1 region of the hippocampus. We obtained a power of 80–90% for the different antibodies to distinguish between the neuropathologically defined groups.
Furthermore, when using antibodies against N-t and C-t, normal nuclear TDP-43 was detected. Non-stained “ghost” NFT-like structures and GVD were occasionally observed with these antibodies in p-preAD and ADTDP + CTF cases (Fig. 4 f2-f3, g2-g3, arrowheads).
ADTDP + FL and FTLD-TDP groups displayed a very similar neuropathological profile regarding all TDP-43 species in most regions (Fig. 3 a-c; Additional file 1-Fig. A1-A3). FTLD-TDP cases still displayed a higher abundance of pTDP403/404, C- and N-t TDP-43 lesions in most regions when compared to ADTDP + FL cases (Additional file 1-Fig. A3).
Morphologically, a few non-AD, p-preAD and ADTDP + CTF cases displayed GVD, large NCIs, few DNs and NFT-like material (Fig. 4 d2, c3-d3, arrows; Additional file 1-Fig. A1-e2-e3). ADTDP + FL cases, as well as FTLD-TDP cases displayed abundant DNs (Fig. 4 c4–5, d4–5, e4–5; Additional file 1- Fig. A1-A2) as well as NCIs (Fig. 4 f4,g4, arrows; Additional file 1-Fig. A1-A2).
Of note, whenever inclusions were detected in the cytoplasm with antibodies against C- or N-t-TDP-43, the nucleus was depleted of normal TDP-43, namely in ADTDP + FL and FTLD-TDP cases (Fig. 4 f4, g4; Additional file 1-Fig. A2-a4-a5 and d4-d5 arrows).
In addition, nuclear clearance of C-t TDP-43 was present in ADTDP + CTF cases, and even more pronounced in ADTDP + FL and FTLD-TDP cases. However, this was purely observational and it was not quantified.
To further investigate the TDP-43 aggregate composition, we performed fluorescence double-labelling experiments with antibodies raised against N-t and C-t-TDP-43. We confirmed that the inclusions in FTLD-TDP as well as in ADTDP + FL cases prominently exhibited the full-length protein at least in the dentate gyrus (Fig. 5 a-c, j-l), temporal cortex (Fig. 5 d-f,m-o) and frontal cortex (Fig. 5 g-i,p-r). A minority of inclusions were exclusively positive for C-t-TDP-43 in these regions as well (Fig. 5 c,i,o - insets).
Distribution of TDP-43 pathology in AD and FTLD
In ADTDP + FL, as well as in FTLD-TDP cases, all regions were affected by pTDP-43409/410 and pTDP-43409 pathology in 50–100% of positive cases (Additional file 1-Tables A3-A4). This was also true for C-t TDP-43, where 45,5–100% cases of these two groups were positive for this antibody in the investigated regions except for NBM (Additional file 1-Table A6). Furthermore, all regions except for NBM and occipital cortex were positive for pTDP403/404 in 45.5–100% of cases ADTDP + FL cases, whereas 50–100% of FTLD-TDP cases were positive for this antibody in the investigated regions, including NBM and occipital cortex (Additional file 1-Table A5). The number of severely affected regions was lower with an antibody against N-t-TDP-43. Nevertheless, in ADTDP + FL cases at least seven regions were heavily impacted by N-t-TDP-43 pathology, and all investigated regions except for NBM showed lesions detectable with this antibody (Additional file 1-Table A7). Similarly, in FTLD-TDP cases, all regions except for NBM and occipital cortex were considerably affected by N-t TDP-43 positive lesions (Additional file 1-Table A7). This means that despite ADTDP + FL and FTLD-TDP cases were molecularly similar in terms of TDP-43 species, FTLD-TDP cases showed a more widespread distribution of TDP-43 pathology.
On the other hand, in p-preAD cases, as well as ADTDP + CTF cases, the pTDP-43409/410 and pTDP-43409 pathology seemed to be mainly restricted to the medial temporal lobe incl. Amygdala, with the exception of the dentate gyrus of the hippocampus, which was generally spared (Additional file 1-Tables A3). Therefore, the most affected regions were amygdala, CA1, subiculum and entorhinal cortex (56.7–90% of ADTDP + CTF cases) whereas the frontal and occipital cortices were less affected (up to 44.8 and 14.3% of positive cases, respectively). Similarly, in the non-AD cases with pTDP-43409/410 pathology, these lesions were also restricted to the medial temporal lobe, incl. Amygdala.
LATE-NC distribution in ADTDP + CTF and ADTDP + FL
We classified our cases that were not typical FTLD-TDP with the recently proposed staging scheme for TDP-43 pathology by Nelson and colleagues . Therefore, we considered LATE-NC positive whenever cases were older than 60 years and had at least pTDP-43 pathology (Table 2, Additional file 1- Table A1). We observed that a minority of non-AD cases displayed LATE-NC stage 1 or 2 (5 or 10%, respectively), meaning that the TDP-43 pathology was limited to the amygdala and hippocampal formation, whereas the remaining control cases did not display LATE-NC (Fig. 6). This was either because they were too young to be considered part of the LATE-NC spectrum and/or because there was no TDP-43 pathology. Around half of p-preAD and ADTDP + CTF cases showed TDP-43 pathology in LATE-NC stage 2, extending into the hippocampus (50% and 63,3%, respectively), whereas 31,3% of p-pre AD cases did not show LATE-NC. Additionally, 30% of ADTDP + CTF cases displayed TDP-43 pathology extending to the frontal cortex (LATE-NC stage 3, Fig. 6).
As for the ADTDP + FL cases, more than half of the cases (54,5%) presented LATE-NC stage 3, whereas the remaining cases were classified as stage 2 LATE-NC (Fig. 6). These findings corroborate our previous results and further demonstrate that in ADTDP + CTF cases, TDP-43 pathology was mostly restricted to the limbic system, whereas the TDP-43 pathology in ADTDP + FL cases was more frequently widespread in the brain.
Relationship of molecular TDP-43 patterns with other AD-related neuropathological lesions
Notably, ADTDP + FL cases were not distinguishable from ADTDP + CTF cases and ADTDP- regarding Aβ, neuritic plaque and NFT pathology (Braak NFT stages III-VI, AβMTL phases 3–5; CERAD score: 1–3; NIA-AA stage 2–3) (p = 1, Fig. 4 a3-a4,b3-b4, Fig. 7 a-d). Kruskall-Wallis with Bonferroni correction for multiple testing was used. For these neuropathological parameters, a post-hoc power analysis revealed a power of 100% for the differences observed among all six groups of cases. The majority of non-AD, control cases (75%) presented PART (Fig. 7 a, Additional file 1-Table A1). Moreover, 2 out of the 3 non-AD cases with TDP-43 pathology mentioned earlier were contemplated among the PART group.
Furthermore, the dementia scores from ADTDP + FL and FTLD-TDP cases (CDR score 2–3) were not significantly different from ADTDP- as well as ADTDP + CTF cases (CDR score 0.5–3) (p = 1, Fig. 7 e). By definition, no signs of dementia were observed in control and p-preAD cases.
Age at death differed significantly between groups when using Kruskall-Wallis test, specifically between non-AD controls and p-preAD: the p-preAD group was on average older than the controls (p = 0.002). The non-AD cases were also significantly younger than the ADTDP- (p < 0.0001), ADTDP + CTF (p < 0.0001), and ADTDP + FL cases (p = 0.003, Fig. 7 f). There were no significant differences in the age of ADTDP-, ADTDP + CTF, ADTDP + FL and FTLD-TDP cases (0.108 < p ≤ 1, Fig. 7f). In line with these results, we performed binary logistic regression to address the differences of Braak NFT-stages, AβMTL phases, CERAD scores and NIA-AA degrees of AD pathology among ADTDP + CTF and ADTDP + FL groups, when controlled for age and sex. We observed that there were no significant differences among these two groups and ADTDP- with ADTDP + FL cases in all parameters analyzed after correction for multiple testing (Additional file 1- Tables A8-A11). Only when comparing ADTDP- with ADTDP + CTF cases, higher Braak NFT stages, AβMTL phases, CERAD scores, and NIA-AA degrees of AD pathology were observed in ADTDP + CTF cases (Additional file 1- Tables A8-A11).
We then tested by binary logistic regression (while controlling for age at death and sex) if there was an association between the molecular patterns identified here with the morphological types of TDP-43 lesions as previously described by Josephs et al. . In this study, the authors defined two morphological types of TDP-43 pathology in non-FTLD brains: type α – DNs, NIIs or NCIs widespread in the brain, and type β – NFT-associated material, restricted to the medial temporal lobe. We classified our cases according to this system (see Additional file 1-Table A1). We further classified all our cases with the molecular patterns found in this study: ‘TDP + CTF’ pattern, positive for pTDP409, and pTDP409/410; or ‘TDP + FL+’ pattern, positive for all TDP-43 markers. The ‘TDP + CTF’ pattern (present in some controls, most p-preAD and all ADTDP + CTF cases) was strongly associated with type β (p < 0.0001, Additional file 1-Table A12) characterized by NFT-like lesions. The ‘TDP + FL’ pattern (observed in ADTDP + FL and FTLD-TDP cases) did neither show an association with type α nor with type β (Additional file 1-Table A13). We analyzed each molecular pattern individually due to collinearity effects. In our cases, we did not observe pure type α pattern. This pattern was always associated with at least few NFT-like TDP-43 inclusions and, therefore, considered as type α + β.
Association of the TDP-43 molecular patterns with clinical phenotypes
To further investigate these molecular patterns statistically, we re-grouped our cohort according to the clinical diagnosis: non-demented (including the neuropathological non-AD and p-preAD cases, n = 36), symptomatic AD (sympAD = all cases with a typical AD phenotype, n = 40), AD/FTD (cases with signs of both AD and FTD symptoms such as behavioral and/or language problems, n = 5) and FTD cases (cases with a clinical FTD phenotype, n = 15). We found that even when grouping our cases based on clinical phenotype, we observed significant differences in the prevalence of pTDP409/410, pTDP409, pTDP403/404, C- and N-t-TDP-43 reactivity, particularly in sympAD cases (Fig. 3 d-f, Additional file 1-Fig. A4) whereas no differences were observed in non-demented individuals (Additional file 1-Table A14, A15). Specifically, in sympAD we observed significant differences between the positivity for both pTDP409/410 and pTDP409 when compared to pTDP403/404, C- and N-t TDP43 in CA1 region and temporal cortex (p ≤ 0.001 and p < 0.047, Fig. 3 e-f). Moreover, significant differences were observed in the staining pattern between these antibodies in the remaining sub-regions of the hippocampus such as CA4, CA3/2, subiculum, as well as entorhinal, amygdala and NBM in sympAD (p < 0.01, Additional file 1-Fig. A4a-f, Additional file 1-Table A15). SympAD cases displayed a lower prevalence of all antibodies in frontal and occipital cortices, therefore there were no significant differences in these regions (Additional file 1-Fig. A4g-h Additional file 1-Table A15).
Moreover, there were no significant differences in positivity of the TDP-43 lesions between the anti-TDP-43 antibodies in the clinical AD/FTD group nor in the FTD group (Additional file 1-Tables A16-A17).
To further confirm the differences in the molecular profile among the clinical groups, we used multinomial logistic regression controlled for age and sex in the most severely affected region (CA1). For this, we used the sympAD group as a reference category. Consistent with our previous results, we observed significant differences between the sympAD and the FTD group regarding the prevalence of pTDP409/410 (p = 0.023), pTDP-43403/404 (p = 0.001), C- and N-t TDP-43 (p = 0.001), but not pTDP-43409 (Additional file 1-Tables A18-A22). This strengthens the hypothesis that the patterns of TDP-43 species differ among these dementias. Furthermore, the positivity for pTDP-43409/410 and pTDP-43409 was lower in non-demented cases, when compared to sympAD cases (Additional file 1-Tables A18-A19). Of note, age at death of FTD cases was lower than that of the sympAD cases. This was also true for non-demented cases (Additional file 1-Tables A18-A22). When using age as the only independent variable through multinomial logistic regression, we confirmed that the sympAD cases were significantly older than the FTD cases (p = 0.002, odds ratio = 1.1).
Clinically, all ADTDP- cases had a clinical AD phenotype (Table 2). Twenty-four out of 30 ADTDP + CTF cases (80%) presented typical AD symptoms in life, such as amnestic deficits and executive dysfunction. Four ADTDP + CTF cases (13,3%) exhibited prominent language problems, with an initial diagnosis of semantic variant-primary progressive aphasia (svPPA). Interestingly, one ADTDP + CTF case (3,3%) showed an AD clinical phenotype and motor speech deficits later on in the disease. Another ADTDP + CTF case (3,3%) presented both clinical AD and behavioral problems, such as impulsivity and aggression (Table 2).
The ADTDP + FL cases presented a larger variety of symptoms ranging from AD to FTD features. Specifically, 7 out of 11 ADTDP + FL cases (63,6%) exhibited a classical AD clinical phenotype – memory deficits and executive dysfunction - whereas 2 ADTDP + FL cases (18,2%) had a diagnosis of the behavioral variant of FTD (bvFTD), with pronounced behavioral problems. Moreover, 1 ADTDP + FL case (9,1%) with the C9ORF72 mutation displayed behavioral FTD-like deficits as well as AD symptoms such as memory deficits. Finally, one ADTDP + FL case (9,1%) displayed svPPA during life, with additional AD signs later on (Table 2, Additional file 1-Table A1).
As for FTLD-TDP cases, 5 out of 10 cases (50%) presented a bvFTD clinical presentation, 3 cases (30%) had svPPA, one case (10%) presented an AD phenotype but later evolved to a bvFTD-like presentation. Another FTLD-TDP case (10%) displayed clinical signs of progressive supranuclear palsy (PSP), due to additional PSP neuropathology (Table 2).
Interestingly, we observed that the ADTDP + FL cases with a Josephs’ morphological pattern type β in the absence of type α features (see additional file 1- Table A1) were clinically typical AD whereas the presence of type α features was observed in 57.1% of the ADTDP + FL cases with FTD symptomatology. To address this, we performed a binary logistic regression using Josephs’ type α as a dependent variable and FTD symptoms, age at death and sex as independent variables. We observed an association between Josephs’ type α and FTD symptoms (p = 0.039), but not between type β and FTD symptoms (p = 0.999), as expected (Additional File 1-Tables A23–24).
Finally, we addressed whether the different TDP-43 molecular patterns identified in this study are statistically associated with different clinical manifestation of the disease. For this, we only considered the demented cases with TDP-43 pathology and performed binary logistic regressions, while controlling for age at death and sex. We found that the ‘TDP + CTF’ molecular pattern was statistically associated with typical AD symptoms - amnestic syndrome executive dysfunction – and that age at death was also associated with clinical AD (Table 3) but inversely associated with FTD symptoms (Additional file 1- Table A25). In turn, the ‘TDP + FL’ pattern, observed in ADTDP + FL as well as FTLD-TDP cases, was significantly associated with a clinical presentation of the FTD spectrum – cases that presented behavioral problems or language deficits (Table 4) - and inversely associated with clinical AD (Additional file 1- Table A26). Post-hoc power analysis of these comparisons among the clinical phenotypes revealed a power 48–87% when considering the typical AD symptoms (87%) and FTD symptoms with or without AD-type cognitive impairment (48%) in each neuropathological group.
In our study, we aimed to clarify the molecular characteristics of TDP-43 aggregates in AD cases with TDP-43 pathology.
We identified distinct molecular patterns of TDP-43 species in neuropathologically-confirmed AD cases. One pattern exhibiting pTDP-43409/410, pTDP-43409, pTDP-43403/404, and non-phosphorylated N- and C-terminal epitopes of TDP-43 indicated the presence of full-length TDP-43 aggregates with a complex phosphorylation pattern including multiple phosphorylation sites. AD cases showing this pattern were referred to as ADTDP + FL. This TDP-43 epitope exhibition pattern was also found in FTLD-TDP cases. The other pattern - seen in most p-preAD cases and in ADTDP + CTF cases was restricted to material stained with the anti-pTDP-43409 and pTDP-43409/410 antibodies, lacking pTDP-43403/404 and rarely positive for non-phosphorylated epitopes of TDP-43. Additionally, 19,6% of all AD cases lacked pTDP-43 inclusions and were considered as ADTDP- cases. Accordingly, TDP-43 pathology in AD showed a spectrum ranging from the complete absence of TDP-43 lesions in ADTDP- cases to ADTDP + CTF, and finally to ADTDP + FL cases with a molecular pattern similar to FTLD-TDP cases (Fig. 8).
Serines 403/404 and 409/410 have been previously described as TDP-43 sites that are abnormally phosphorylated in the brains of ALS and FTLD-TDP and AD patients [2, 18, 30]. However, it is not yet clear whether pathomechanistic variations are responsible for these different phosphorylation patterns among TDP-43 proteinopathies. Our findings support the hypothesis that phosphorylation at distinct sites of TDP-43 has impact on the molecular type of AD-related TDP-43 pathology and its relation to FTD symptoms. Clinically, 80% of the ADTDP + CTF cases were characterized by typical AD symptoms with leading amnestic and cognitive decline and only 20% of the cases by language problems indicative for PPA. The ADTDP + FL cases presented typical AD symptoms in 63,6% and FTD-like symptoms, such as behavior or language problems in 36,4%.
Morphologically, the majority of TDP-43 lesions in ADTDP + CTF cases consisted of large NCIs, few DNs and NFT-like structures, consistent with previous studies [26, 39]. On the other hand, ADTDP + FL cases displayed abundant DNs and NCIs, as well as NFT-like structures in some cases, which were particularly predominant in temporal and frontal cortices. Of note, we observed no strict association to a specific FTLD-TDP subtype (A-D) as defined by Mackenzie et al , considering that there was morphological variability in the ADTDP + FL cases as in FTLD-TDP. Moreover, 4 out of the 11 ADTDP + FL cases did not fit into any FTLD-TDP subtype. These cases displayed large, TDP43-positive NCIs and few DNs scattered among all layers of the temporal cortex and were clinically AD cases. Nevertheless, all ADTDP + FL cases presented a common molecular pattern, which was the focus of our study. Importantly, this pattern was also observed in the typical FTLD-TDP cases. Moreover, Josephs et al.  recently studied the morphology of TDP-43 lesions in non-FTLD cases. They identified two morphological signatures for their cases: one related to NCIs and DNs distributed widespread over the brain including frontal cortex (type α), and another related to NFT-associated TDP-43 inclusions, restricted to the medial temporal lobe (type β). Our results corroborate these data in the sense that all ADTDP + CTF and 45,4% of ADTDP + FL cases display type β, whereas the remaining 54,5% of the ADTDP + FL cases present features of both types, α and β, considering that they exhibited not only dystrophic neurites and NCIs in a widespread distribution, but also NFT-associated neuronal inclusions. Thus, we extend this knowledge by distinguishing distinct molecular patterns of TDP-43 species, with the ‘TDP + CTF’ pattern being significantly associated to type β whereas type α features were restricted to a subset of ADTDP + FL cases. Interestingly, these ADTDP + FL cases with a type α TDP-43 pattern were those to show FTD symptoms in 57% of the cases whereas none of our ADTDP + FL cases without type α features, i.e. without frontal or temporal TDP-43 pathology, exhibited signs of FTD. Thus, we can conclude that TDP-43 pathology in AD can cause FTD symptoms when TDP-43 lesions extent into the cortex. This argues strongly in favor of similar underlying processes in FTLD-TDP and ADTDP + FL with cortical TDP-43 pathology, probably to coexisting AD and FTLD-TDP in ADTDP + FL cases. Interestingly, 4 ADTDP + FL cases that were considered as Josephs’ type β were symptomatically AD. In turn, Josephs’ type α was statistically associated with FTD symptoms, which makes it tempting to speculate that type α may play a role in the FTD symptomatology, however more investigation regarding the association of types α and β with clinical symptoms needs to be done.
A few non-AD controls, as well as cognitively normal p-preAD cases also presented TDP-43 proteinopathy, consistent with other studies that observed TDP-43 pathology in cognitively normal individuals [3, 40, 45, 67], which was associated with PART [28, 68]. The TDP-43 molecular pattern in these cases was similar to that seen in ADTDP + CTF cases, as well as the morphology of these lesions, which consisted of NFT-associated material, reflecting Josephs’ type β TDP-43 pathology.
Overall, these results point to a potential difference in the mechanism of TDP-43 proteinopathy between ADTDP + CTF and ADTDP + FL, with the latter similar to that of FTLD-TDP. Our results also indicate that C-terminal fragments (CTFs) of TDP-43 are enriched in ADTDP + CTF, consistent with other studies . Such mechanisms could be related to different kinases phosphorylating serines 403/404 and 409/410, considering that the pattern of phosphorylation at these sites distinguishes these groups of cases. Alternatively, genetic differences could also explain the distinct neuropathological TDP-43 patterns [26, 47]. Interestingly, one case in the ADTDP + FL group had a mutation in an FTLD-TDP causing gene, i.e. in the C9ORF72 gene [13, 55]. This supports our interpretation of the ‘TDP + FL’ pattern as possibly biologically linked to FTLD-TDP at least in some of these cases probably exhibiting co-existing AD and FTLD-TDP. On the other hand, the C9ORF72 mutation has been previously found in a very low amount of AD cases .
A third explanation for the different patterns of TDP-43 pathology in AD cases could be that TDP-43 plays different roles in these patients. In AD, the accumulation of presumably N-terminal truncated pTDP-43409/410 may represent a secondary event, maybe co-seeded by τ or Aβ, as hypothesized by others [12, 20, 36]. An argument supporting this hypothesis is that TDP-43 pathology in our control cases occurred in the same anatomical regions, in which PART-lesions (NFTs and neuropil threads) were co-existing. The morphological appearance of the TDP-43 lesions in ADTDP + CTF cases as NFTs may also argue for a secondary phenomenon induced by the underlying τ pathology [1, 60]. Non-specific detection of NFTs by anti-TDP-43409/410 antibodies has also been discussed . However, in our study three different antibodies against pTDP-43409/410, including a monoclonal antibody, labelled NFTs, arguing against non-specific staining. Furthermore, all of our ADTDP + CTF cases had high amounts of τ protein pathology in the frontal cortex, but no anti-pTDP-43409/410 or anti-pTDP-43409 positive material, which also argues against non-specific labelling of anti-pTDP-43 antibodies in the hippocampus or the amygdala. This is strengthened by the reports of other authors that NFT-like material can be detected with non-phosphorylated anti-TDP-43 antibodies [1, 26], which suggests a strong association between τ and TDP-43. On the other hand, one may speculate that TDP-43 acts as the primary pathology in ADTDP + FL cases, similarly to FTLD-TDP. In light of these arguments, it is tempting to speculate that both secondary accumulation of TDP-43 and primary TDP-43 pathology may occur in AD cases: Secondary accumulation of pTDP43409/410 and pTDP-43409-positive material in ADTDP + CTF cases and primary development of TDP-43 aggregates in ADTDP + FL cases.
There has been growing evidence regarding the existence of concomitant neuropathologies, in which a neurodegenerative disease might have additional aggregated proteins besides the primary pathology, accumulating as co-pathologies [4, 15, 32, 57, 63]. ADTDP + FL cases described in this study appear to be an example of this, as they present a molecular pattern of TDP-43 pathology similar to that seen in FTLD-TDP cases, as well as histological full-blown AD pathology (as observed with antibodies against Aβ and τ). Furthermore, 7 of these 11 cases presented a morphological and topographic distribution of TDP-43 compatible with one of the FTLD-TDP subtypes (A-C). This stresses the importance of considering multiple pathologies contributing to the development of dementia, as seen in previous studies . The recent consensus work regarding LATE might also be important in this context . LATE-NC was described as the presence of TDP-43 pathology in the limbic areas of elderly, with or without co-existing AD pathology. As seen here, a few non-AD controls, the majority of p-preAD and all ADTDP + CTF, as well as ADTDP + FL cases fit into this new classification (Table 2, Additional file 1-Table A1). The controls, p-preAD, and ADTDP + CTF cases that exhibited LATE-NC, mostly presented LATE-NC stage 2, which means the TDP-43 pathology is predominantly present in amygdala and hippocampus. On the other hand, 54,5% of ADTDP + FL cases had additional TDP-43 lesions in the frontal cortex, indicative for LATE-NC stage 3. Of note, 19,6% of all neuropathologically-confirmed AD cases did not present TDP-43 pathology (i.e LATE-NC) at all, consistent with other studies [44, 47]. Interestingly, the p-preAD cases in our cohort showed a high prevalence of TDP-43 pathology, reflected in the 68,7% of cases with LATE-NC stage 1 or stage 2. Given the hierarchical detectability of first pTDP-43409 and pTDP-43409/410 in cases with LATE-NC stages 1–2 and second other TDP-43 epitopes in ADTDP + FL cases with LATE-NC stages 2 and 3, one could hypothesize that TDP-43 aggregates in AD undergo maturation changes similar to Aβ aggregates . An argument against this hypothesis is that both AD-related τ and Aβ pathology showed late stages of AD pathology in ADTDP-, ADTDP + CTF and ADTDP + FL cases, and that there was no significant difference in age among these groups. Secondly, the identification of one ADTDP + FL case with a C9ORF72 gene mutation strongly suggests a specific FTLD-like influence of TDP-43 pathology in at least a subset of these cases and, thereby, also argues against a simple maturation process of TDP-43 aggregates that distinguishes ADTDP + CTF and ADTDP + FL cases. In our opinion, it is therefore likely that the different molecular patterns of TDP-43 pathology among AD cases may constitute subtypes of LATE-NC or alternatively argue in favor of spectrum of AD ranging from ADTDP- without TDP-43 pathology to ADTDP + FL with probably coexisting FTLD pathology. However, the LATE concept is controversial and further investigation addressing the morphology of these lesions and its relationship to the molecular and clinical patterns is needed. Nevertheless, if these patterns constitute subtypes of LATE-NC, the umbrella term ‘LATE-NC’ could include different molecular types of TDP-43 lesions that give rise to the hypothesis that LATE-NC covers biologically different lesions/diseases: 1. TDP-43 pathology with predominance of phosphorylated C-terminal fragments of TDP-43 as in ADTDP + CTF, 2. full-length TDP-43 pathology as in ADTDP + FL similar as in FTLD-TDP, 3. hippocampal sclerosis, and maybe others that we are not yet aware of. Whether the full-length TDP-43 predominant pattern in ADTDP + FL cases distinguishes co-existing FTLD-TDP pathology from the C-terminal fragment-predominant lesions, needs to be clarified in the future.
Importantly, the ‘TDP + CTF’ molecular pattern (observed in some non-AD, most p-preAD and ADTDP + CTF cases) was significantly associated with typical AD symptoms, whereas the ‘TDP + FL’ molecular pattern (observed in ADTDP + FL and FTLD-TDP cases) was associated with symptoms of the FTD spectrum, especially in those ADTDP + FL cases that exhibit TDP-43 lesions in the frontal and/or temporal neocortex, i.e. representing the type α TDP-43 distribution pattern (Fig. 8). This suggests that the molecular profile of TDP-43 species in these cases together with the cortical distribution of the lesions influences the clinical presentation of the disease to a certain degree. However, typical AD symptoms were seen in more than 50% of the cases in both AD subgroups. This indicates that the ‘TDP + FL’ molecular pattern had impact on less than 50% of the cases with various phenotypes typical of the FTD spectrum (36,4%). Interestingly, in the ADTDP + CTF group, less than 20% of the cases showed other symptoms besides cognitive deficits and executive dysfunction. These were related to language alterations in 16,6% of the cases, with only 1 case showing additional behavioral changes.
AD and LATE-NC can occur in the same individuals and both are associated with cognitive decline and amnestic symptoms, whereas FTLD-TDP is characterized by alterations in behavior and/or language . It has been shown that the co-existence of LATE-NC and AD pathology is associated with clinically more severe symptoms than pure AD (in the absence of TDP-43 pathology, i.e. LATE-NC) . Indeed, TDP-43 has been demonstrated to worsen cognition in aged individuals [29, 31, 46, 53], probably due to a synergistic effect with τ protein [37, 60]. The ADTDP + FL cases in our cohort presented a broad range of clinical phenotypes, from a primary amnestic deficit (typical for AD) to personality and language changes (typical for FTD). This has impact on the clinical differential diagnosis of degenerative dementing disorders. On the one hand, cases presenting a clinical phenotype of the FTLD spectrum may display significant levels of AD pathology, as seen in our results, which might be associated with positive AD biomarkers. This is also valid for those ADTDP + CTF cases that presented a svPPA phenotype. On the other hand, cases exhibiting a typical AD clinical phenotype and biomarker profile might present a widespread FTLD-TDP-like TDP-43 pathology and molecular pattern as well. Thus, AD-related treatments might possibly be less effective than expected in these cases. This may also have implications for clinical praxis, in the sense that the screening for AD biomarkers in cases with a clinical picture of FTD might be relevant. This would avoid missing AD lesions in ADTDP + FL cases. Overall, our data highlight the relevance of underlying pathologies for the diagnosis and treatment of patients.
One limitation of this study is that the post-mortem intervals of the cases in our cohort were variable (24 to 120 h). Furthermore, the fixation time was also variable (2–4 weeks) due to the fact that the sample consists of several hospital-based cohorts, in which the tissue was acquired at different time-points. However, we did not observe obvious differences in the TDP-43 staining quality among our cases, indicating that these limitations had no significant impact on our results. Another limitation is that there is not a standard TDP-43 antibody recommended to characterize TDP-43 proteinopathies. To overcome this problem, we chose several commercially available, phosphorylation dependent and independent antibodies to provide reliable results. In addition, the number of ADTDP + FL and FTLD-TDP cases was limited (eleven and ten, respectively). The difference in age distribution among the groups and the use of hospital-based cohorts may be considered as another limitation of this study. Logistic regressions controlling for age at death showed that especially controls and FTLD-TDP cases were younger compared to the AD group. This could be due to the low number of cases. However, the younger age of death of control cases free of any AD pathology can be expected, as in older individuals we often observe AD-related pathology. Therefore, only few cases at higher ages may serve as non-AD controls [8, 62], leading to the selection of younger cases as controls compared to older ones with full-blown AD. To take this age difference into account in our analyses, we included age and sex in logistic regression models as additional independent variables. Finally, the low number of cases with distinct clinical phenotypes in the ADTDP + FL group is another limitation. To determine the impact of this limitation, we performed a post-hoc power analysis for our data and obtained a statistical power of ≥80% when analyzing the different TDP-43 antibody patterns among the disease groups, as well as other neuropathological parameters (i.e.: Braak NFT-stages, AβMTL phases, CERAD score, etc). For the clinical parameters, we had a statistical power of 48–87% indicating that the interpretation of our results is solid for the neuropathological groups and parameters. Conclusions about clinical phenotypes/parameters, on the other hand, must be considered with caution. Since we did not have a community-based cohort of cases, we cannot exclude influence of the hospital-based sampling on our results. However, the prevalence of TDP-43 pathology in elderly individuals of community-based samples in the literature showed a similarly high prevalence of TDP pathology in the brain [24, 40].
In conclusion, we were able to identify molecular differences in TDP-43 pathological lesions, distinguishing distinct patterns of TDP-43 pathology in neuropathologically-confirmed AD cases, one of which being similar to the pattern observed in FTLD-TDP. These patterns differed in the prevalence of truncated and non-truncated TDP-43 species and of distinct phosphorylation epitopes. Furthermore, we showed that these patterns were associated with the frequency of FTD symptoms. These differences may have an impact for future diagnostic algorithms and treatment of patients with clinical signs of dementia. Therefore, underlying pathologies need to be considered when diagnosing and consequently treating demented patients. Whether these molecular patterns of TDP-43 pathology represent types of LATE-NC and, thereby, are features of one disease entity (LATE) or whether they represent a spectrum of late-life neuropathologies in AD ranging from ADTDP- to ADTDP + CTF and finally ADTDP + FL with molecular similarities to FTLD-TDP needs to be explored in the future.
Availability of data and materials
The anonymized datasets used and/or analyzed during the current study are stored in UZ/KU-Leuven network drives and available from the corresponding author on reasonable request.
Transactive Response DNA-Binding Protein
phosphorylated tau protein
pathologically-defined preclinical AD
Frontotemporal lobar degeneration with TDP-43 inclusions
Neuronal cytoplasmic inclusions
- ADTDP- :
Neuropathologically-confirmed AD cases without TDP-43 pathology
- ADTDP + CTF :
Neuropathologically-confirmed AD cases with pTDP-43 pathology but no non-phosphorylated or pTDP-403403/404 pathology
- ADTDP + FL :
Neuropathologically-confirmed AD cases with TDP-43 pathology positive for all markers in this study
Limbic-predominant age-related TDP-43 encephalopathy
Limbic-predominant age-related TDP-43 encephalopathy related neuropathological changes
semantic variant of primary progressive aphasia
Progressive supranuclear palsy
Amador-Ortiz C, Lin W-L, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445. https://doi.org/10.1002/ana.21154
Arai T, Mackenzie IRA, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136. https://doi.org/10.1007/s00401-008-0480-1
Arnold SJ, Dugger BN, Beach TG (2013) TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 126:51–57. https://doi.org/10.1007/s00401-013-1110-0
Attems J, Jellinger K (2013) Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res 10:569–577
Berning BA, Walker AK (2019) The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci 13:1–27. https://doi.org/10.3389/fnins.2019.00335
Braak H, Alafuzov I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404. https://doi.org/10.1007/s00401-006-0127-z
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969. https://doi.org/10.1097/NEN.0b013e318232a379
Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, Fang L, Van Deerlin VM, Ludolph AC, Lee VM-Y, Braak H, Trojanowski JQ (2014) Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 127:423–439. https://doi.org/10.1007/s00401-013-1238-y
Cohen TJ, Lee VMY, Trojanowski JQ (2011) TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med 17:659–667. https://doi.org/10.1016/j.molmed.2011.06.004
Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766. https://doi.org/10.1007/s00401-014-1349-0
Davis SA, Ann Gan K, Dowell JA, Cairns NJ, Gitcho MA (2017) TDP-43 expression influences amyloidβ plaque deposition and tau aggregation. https://doi.org/10.1016/j.nbd.2017.04.012
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC Hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256. https://doi.org/10.1016/j.neuron.2011.09.011
Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890. https://doi.org/10.1016/S0006-291X(84)80190-4
Gomes LA, Hipp SA, Rijal Upadhaya A, Balakrishnan K, Ospitalieri S, Koper MJ, Largo-Barrientos P, Uytterhoeven V, Reichwald J, Rabe S, Vandenberghe R, von Arnim CAF, Tousseyn T, Feederle R, Giudici C, Willem M, Staufenbiel M, Thal DR (2019) Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein. Acta Neuropathol 138:913–941. https://doi.org/10.1007/s00401-019-02053-5
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014. https://doi.org/10.1212/WNL.0b013e31821103e6
Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, Carrell D, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, Mayeux R, Chakraverty S, Goate AM, Cruchaga C (2013) C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 70:736–741. https://doi.org/10.1001/2013.jamaneurol.537
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I, Oda T, Tsuchiya K, Akiyama H (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64:60–70. https://doi.org/10.1002/ana.21425
Hecht M, Krämer M, Von Arnim CAF, Otto M, Thal DR (2018) Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol 135:681–694. https://doi.org/10.1007/s00401-018-1834-y
Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H (2007) Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294. https://doi.org/10.1016/J.BRAINRES.2007.09.048
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007
Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, McCluskey LF, Trojanowski JQ, Lee VM-Y (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173:182–194. https://doi.org/10.2353/ajpath.2008.080003
Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle FE, Akiyama H, Hisanaga S, Hasegawa M (2008) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 582:2899–2904. https://doi.org/10.1016/j.febslet.2008.07.027
James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain 139:2983–2993. https://doi.org/10.1093/brain/aww224
Josephs KA, Mackenzie IR, Frosch MP, Bigio EH, Neumann M, Arai T, Dugger BN, Ghetti B, Grossman M, Hasegawa M, Herrup K, Holton J, Jellinger K, Lashley T, McAleese KE, Parisi JE, Revesz T, Saito Y, Vonsattel JP, Whitwell JL, Wisniewski T, Hu WT (2019) Late to the party. Brain 357:1–5. https://doi.org/10.1126/science.357.6347.160-d
Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Ralph PB, Perkerson B, Matchett BJ, Jack CR Jr, David KS, Petersen RC, Parisi JE, Petrucelli L, Baker M, Rademakers R, Whitwell JL, Dickson DW (2019) Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol 137:227–238. https://doi.org/10.1007/s00401-018-1951-7
Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW (2016) Updated TDP-43 in Alzheimer’s disease staging scheme. Acta Neuropathol 131:571–585. https://doi.org/10.1007/s00401-016-1537-1
Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Serie AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, Petersen RC, Dickson DW (2015) TDP-43 and pathological subtype of Alzheimer’s disease impact clinical features. Annu Rev Neurosci 78:697–709. https://doi.org/10.1002/ana.24493
Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Jack CR, Parisi JE, Petersen RC, Dickson DW, Dickson DW (2014) TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol 127:811–824. https://doi.org/10.1007/s00401-014-1269-z
Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, Hasegawa M (2009) Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun 382:405–409. https://doi.org/10.1016/j.bbrc.2009.03.038
Kapasi A, Yu L, Stewart CC, Schneider JA, Bennett DA, Boyle PA (2019) Association of TDP-43 pathology with domain-specific literacy in older persons. Alzheimer Dis Assoc Disord 1. https://doi.org/10.1097/WAD.0000000000000334
Kim E-J, Brown JA, Deng J, Hwang J-HL, Spina S, Miller ZA, DeMay MG, Valcour V, Karydas A, Ramos EM, Coppola G, Miller BL, Rosen HJ, Seeley WW, Grinberg LT (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960–2971. https://doi.org/10.1007/s00415-018-9086-2
King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S (2010) Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer’s disease. Neuropathology 30:408–419. https://doi.org/10.1111/j.1440-1789.2009.01085.x
Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, Miller BL, Mercaldo N (2008) Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131:2957–2968. https://doi.org/10.1093/brain/awn234
Koper MJ, Van Schoor E, Ospitalieri S, Vandenberghe R, Vandenbulcke M, Von Arnim CAF, Tousseyn T, Balusu S, De Strooper B, Thal DR (2019) Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease. Acta Neuropathol 139:463–484. https://doi.org/10.1007/s00401-019-02103-y
LaClair KD, Donde A, Ling JP, Jeong YH, Chhabra R, Martin LJ, Wong PC (2016) Depletion of TDP-43 decreases fibril and plaque β-amyloid and exacerbates neurodegeneration in an Alzheimer’s mouse model. Acta Neuropathol 132:859–873. https://doi.org/10.1007/s00401-016-1637-y
Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, Henriksen J, Darvas M, Domoto-Reilly K, Jayadev S, Grabowski TJ, Crane PK, Larson EB, Kraemer BC, Bird TD, Keene CD (2019) Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun 7:9. https://doi.org/10.1186/s40478-019-0743-1
Lippa CF, Rosso AL, Stutzbach LD, Neumann M, Lee VMY, Trojanowski JQ (2009) Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch Neurol 66:1483–1488. https://doi.org/10.1001/archneurol.2009.277
Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DMA, Lee VMY (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113. https://doi.org/10.1007/s00401-011-0845-8
McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017) TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol 27:472–479. https://doi.org/10.1111/bpa.12424
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, Ball MJ, Bierer LM, Claasen D, Hansen LR, Hart M, Hedreen J, Baltimore B, Hen Derson V, Hyman BT, Joachim C, Mark-Esbery W, Mar Tinez AJ, McKee A, Miller C, Moossy J, Nochlin D, Perl D, Petito C, Rao GR, Schelper RL, Slager U, Terry RD (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486. https://doi.org/10.1212/wnl.41.4.479
Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414. https://doi.org/10.1212/WNL.43.11.2412-A
Nag S, Yu L, Wilson RS, Chen E-YY, Bennett DA, Schneider JA (2017) TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology 88:653–660. https://doi.org/10.1212/WNL.0000000000003610
Nascimento C, Di AT, Alho L, Bazan C, Amaral C, Elane R, Leite P, Nitrini R, Jacob-Filho W, Pasqualucci CA, Rosa S, Hokkanen K, Hunter S, Keage H, Kovacs GG, Grinberg LT, Suemoto CK Prevalence of TDP-43 proteinopathy in cognitively normal older adults: systematic review and meta-analysis. doi: https://doi.org/10.1111/nan.12430
Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Davis DG, Poduska JW, Patel E, Mendiondo MS, Markesbery WR (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20:66–79. https://doi.org/10.1111/j.1750-3639.2008.00244.x
Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White Iii CL, Yu L, Schneider JA (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 0:1–25. https://doi.org/10.1093/brain/awz099
Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, Lee VM-Y (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117:137–149. https://doi.org/10.1007/s00401-008-0477-9
Neumann M, Mackenzie IRA (2018) Neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol:19–40. https://doi.org/10.1111/nan.12526
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM-Y (2006) Ubiquitinated TDP-43 in Frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (80- ) 314:130–133. https://doi.org/10.1126/science.1134108
Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M (2009) Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 18:3353–3364. https://doi.org/10.1093/hmg/ddp275
Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM, Bangen KJ, Delano-wood L, Lamar M, Lim YY, Nudelman K, Zahodne L, Gross AL, Mungas D, Widaman KF, Schneider J (2018) Combined Neuropathological pathways account for age-related risk of dementia. Ann Neurol 84:1–13. https://doi.org/10.1002/ana.25246
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, Van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini M-L, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477. https://doi.org/10.1093/brain/awr179
Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, Alafuzoff I (2013) Consensus recommendations on pathologic changes in the Hippocampus: a postmortem multicenter inter-rater study
Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita V-M, Kaivorinne A-L, Hölttä-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Sabatelli M, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ (2011) A Hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. https://doi.org/10.1016/j.neuron.2011.09.010
Rijal Upadhaya A, Kosterin I, Kumar S, Von Arnim CAF, Yamaguchi H, Fändrich M, Walter J, Thal DR (2014) Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease. Brain 137:887–903. https://doi.org/10.1093/brain/awt362
Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM-Y, Trojanowski JQ (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141:2181–2193. https://doi.org/10.1093/brain/awy146
Rohn TY (2008) Caspase-cleaved TAR DNA binding Protein-43 is a major pathological finding in Alzheimer’s disease. Brain Res 1228:189–198. https://doi.org/10.1016/j.brainres.2008.06.094
Seeley WW (2008) Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr Opin Neurol 21:701–707. https://doi.org/10.1097/WCO.0b013e3283168e2d
Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW, Nelson PT (2018) Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 28:264–273. https://doi.org/10.1111/bpa.12505
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292. https://doi.org/10.1016/j.jalz.2011.03.003
Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134:187–205. https://doi.org/10.1007/s00401-017-1709-7
Takeda T (2018) Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology 38:72–81. https://doi.org/10.1111/neup.12428
Thal DR, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Aβ-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733–748. https://doi.org/10.1093/jnen/59.8.733
Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJM, Rozemuller AJ, Braak H, Knippschild U (2011) Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response. Acta Neuropathol 122:577–589. https://doi.org/10.1007/s00401-011-0871-6
Walker AK, Tripathy K, Restrepo CR, Ge G, Xu Y, Kwong LK, Trojanowski JQ, M-Y Lee V (2015) An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum Mol Genet 24:7241–7254. https://doi.org/10.1093/hmg/ddv424
Wilson AC, Dugger BN, Dickson DW, Wang D-S (2011) TDP-43 in aging and Alzheimer’s disease - a review. Int J Clin Exp Pathol 4:147–155
Zhang X, Sun B, Wang X, Lu H, Shao F, Rozemuller AJM, Liang H, Liu C, Chen J, Huang M, Zhu K (2019) Phosphorylated TDP-43 staging of primary age-related Tauopathy. Neurosci Bull 35:183–192. https://doi.org/10.1007/s12264-018-0300-0
We would like to thank the patients and their families who donated brains to support our research. We thank Dr. Peter Davies, Department of Pathology, Albert Einstein College of Medicine, USA for the gift of the PHF1 antibody. We would also like to thank Alicja Ronisz for all the technical support.
Alzheimer Forschung Initiative (AFI) #13803 (DRT); Fonds Wetenschappelijk Onderzoek (FWO) G0F8516N (DRT, RV); Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043) (RV, DRT); Mady Browaeys Fund for Research into Frontotemporal Lobar Degeneration (RV); BMBF (FTLDc) grant (MO).
Ethics approval and consent to participate
All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases was granted by the ethical committee of Ulm University (Germany) and UZ/KU-Leuven ethical committee (Belgium). This study covering the retrospective analysis of samples and data was approved by the UZ/KU-Leuven ethical committee (S-59295) (Belgium).
Consent for publication
Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
DRT received speaker honorary from Novartis Pharma AG (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).
CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Hong Kong University Research council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2019) and Dr. Willmar Schwabe GmbH &Co. KG (2014–2019).
MO served as consultant for Axon neuroscience and Fujirebio and gave invited talks for Roche and Fujirebio.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure A1. - pTDP-43409/410 species are predominant in p-preAD and ADTDP + CTF whereas ADTDP + FL and FTLD-TDP display positivity for all pTDP-43 epitopes in several regions. Immunohistochemistry of a non-AD, p-preAD, ADTDP + CTF, ADTDP + FL and FTLD-TDP case in dentate gyrus (a,d,h), temporal (b,e,i) and frontal (c,f,j) cortices with (a1-c5) pTDP-43409/410 (clone 1D3), (d1-f5) pTDP-43409 and (h1-j5) pTDP-43403/404, displaying lesions (arrowheads). P-preAD and ADTDP + CTF cases displayed mostly NFT-like inclusions with pTDP-403409 in temporal cortex (e2-e3). ADTDP + FL and FTLD-TDP cases showed NCIs in the DG (a4-a5 respectively, arrowheads), NCIs and DNs in temporal cortex (b4-b5 respectively, arrowheads) and DNs in frontal cortex (c4-c5 respectively, arrowheads) when stained with all pTDP-43 antibodies. ADTDP- cases were not included in this figure because no TDP-43 inclusions were observed. Scale bar = 50 μm. Figure A2. – ADTDP + FL and FTLD-TDP display inclusions positive for non-phosphorylated TDP-43, but not p-preAD or ADTDP + CTF cases. Immunohistochemistry of a non-AD, p-preAD, ADTDP + CTF ADTDP + FL and FTLD-TDP case in dentate gyrus (a, d), temporal (b, e) and frontal (c, f) cortices with C- and N-t TDP-43, displaying cytoplasmic lesions (arrowheads) and nuclear clearance (arrows). ADTDP + FL and FTLD-TDP cases also displayed NCIs in the DG (d4-d5 respectively, arrowheads) with clearance of normal C-t-TDP-43 from the nucleus (a4-a5, arrows), DNs in the temporal cortex (b4-b5 respectively, arrowheads) and DNs in frontal cortex (c4-c5 respectively, arrowheads) when stained with C-t-TDP-43. Finally, ADTDP + FL and FTLD-TDP cases showed NCIs in the DG (d4-d5 respectively, arrowheads) with clearance of normal N-t-TDP-43 from the nucleus (arrows), DNs in the temporal cortex (e4-e5 respectively, arrowheads) and DNs in the frontal cortex (f4-f5 respectively, arrowheads) when stained with N-t-TDP-43. ADTDP- cases were not included in this figure because no TDP-43 inclusions were observed. Scale bar = 50 μm. Figure A3. - Percentage of positive cases for DNs, NCIs, NIIs or NFT-like lesions detected with pTDP-43409/410, pTDP-43409, pTDP-43403/404, C- and N-t-TDP-43 in (a) amygdala, (b) NBM, (c) CA4, (d) CA3/2, (e) subiculum, (f) entorhinal cortex, (g) frontal cortex and (h) occipital cortex. Grouping of cases was done according to the neuropathological criteria for non-AD (n = 20), p-preAD (n = 16), ADTDP- (n = 10), ADTDP + CTF (n = 30) and FTLD-TDP cases (n = 10). ADTDP + FL cases (n = 11) were considered as neuropathologically-confirmed AD cases with a molecular TDP-43 pattern similar to that of FTLD-TDP. Figure A4. – Clinical grouping of our cohort shows significant differences within the different antibodies in the symptomatic AD group. Quantifications of positive cases for DNs, NCIs, NIIs or NFT-like lesions detected with pTDP-43409/410, pTDP-43409, pTDP-43403/404, C- and N-t-TDP-43 in (a) amygdala, (b) NBM, (c) CA4, (d) CA3/2, (e) subiculum, (f) entorhinal cortex, (g) frontal cortex and (h) occipital cortex. Non-parametric, Friedman test for related samples with Bonferroni correction for multiple testing was used to compare the amount of positive cases of each TDP-43 antibody. Each group was analyzed separately, *p < 0.05, **p < 0.01. Non-demented cases included the cases from the non-AD and p-preAD neuropathological groups (n = 36). SympAD cases referred to cases with exclusive AD symptoms (including ADTDP + CTF, ADTDP- and some ADTDP + FL cases, n = 40), AD/FTD refer to cases with both AD and FTD signs (n = 5) and FTD group represents cases with an exclusive FTD presentation (n = 15). Table A1 - Human cases used in this study. Abbreviations; NA: not applicable; na: not assessed; m: male; f: female; PART: primary age-related tauopathy; CAA: cerebral amyloid angiopathy; AGD: argyrophilic grain disease; LBD: Lewy body disease. Table A2- List of antibodies used in this study. Abbreviations; IHC: immunohistochemistry, IF: immunofluorescence; Rb: rabbit, Ms.: mouse; ND: non-determined, N-t: N-terminal, C-t: C-terminal. Table A3- percentage of positive cases for pTDP-43409/410. Table A4- percentage of positive cases for pTDP-43409. Table A5- percentage of positive cases for pTDP-43403/404. Table A6- percentage of positive cases for C-t-TDP-43. Table A7- percentage of positive cases for N-t-TDP-43. Table A8 a – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP + FL regarding Braak NFT-staging, when controlled for age and sex. b – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP-regarding Braak NFT-staging, when controlled for age and sex. c – Binary logistic regression addressing the differences between ADTDP + FL vs. ADTDP-regarding Braak NFT-staging, when controlled for age and sex. * after Bonferroni correction for multiple testing. Table A9 a – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP + FL regarding AβMTL phase, when controlled for age and sex. b – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP- regarding AβMTL phase, when controlled for age and sex. c – Binary logistic regression addressing the differences between ADTDP + FL vs. ADTDP- regarding AβMTL phase, when controlled for age and sex. * after Bonferroni correction for multiple testing. Table A10 a – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP + FL regarding CERAD score, when controlled for age and sex. b – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP- regarding CERAD score, when controlled for age and sex. c – Binary logistic regression addressing the differences between ADTDP + FL vs. ADTDP- regarding CERAD score, when controlled for age and sex. * after Bonferroni correction for multiple testing. Table A11 a – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP + FL regarding NIA-AA degree of AD pathology, when controlled for age and sex. b – Binary logistic regression addressing the differences between ADTDP + CTF vs. ADTDP- regarding NIA-AA degree of AD pathology, when controlled for age and sex. c – Binary logistic regression addressing the differences between ADTDP + FL vs. ADTDP- regarding NIA-AA degree of AD pathology, when controlled for age and sex. * after Bonferroni correction for multiple testing. Table A12 – Binary logistic regression addressing the association of the TDP + CTF pattern with types α and β, controlled for age at death and sex. Cases with type α + β were considered as positive for type α as well as for type β, respectively. Table A13 – Binary logistic regression addressing the association of the TDP + FL pattern with types α and β, controlled for age at death and sex. Cases with type α + β were considered as positive for type α as well as for type β, respectively. Table A14 –P values of comparisons between TDP-43 antibodies for non-demented cases, n = 36. Friedman test with Bonferroni correction for multiple testing. Abbreviations; NBM: basal nucleus of Meynert, DG: dentate gyrus. Table A15 – P values of comparisons between TDP-43 antibodies groups for symptomatic AD cases, n = 33. Friedman test with Bonferroni correction for multiple testing. Abbreviations; NBM: basal nucleus of Meynert, DG: dentate gyrus. Table A16 – P values of comparisons between TDP-43 antibodies groups for AD/FTD cases, n = 5. Friedman test with Bonferroni correction for multiple testing. Abbreviations; NBM: basal nucleus of Meynert, DG: dentate gyrus. Table A17 – P values of comparisons between TDP-43 antibodies groups for FTD cases, n = 15. Friedman test with Bonferroni correction for multiple testing. Abbreviations; NBM: basal nucleus of Meynert, DG: dentate gyrus. Table A18 – Multinomial logistic regressions addressing the differences between disease groups, for pTDP409/410, in CA1 region. Symptomatic AD cases were considered as the reference category for comparison. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Table A19 – Multinomial logistic regressions addressing the differences between disease groups, for pTDP409, in CA1 region. Symptomatic AD cases were considered as the reference category for comparison. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Table A20 – Multinomial logistic regressions addressing the differences between disease groups, for pTDP403/404, in CA1 region. Symptomatic AD cases were considered as the reference category for comparison. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Table A21 – Multinomial logistic regressions addressing the differences between disease groups, for C-t TDP-43, in CA1 region. Symptomatic AD cases were considered as the reference category for comparison. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Table A22 – Multinomial logistic regressions addressing the differences between disease groups, for N-t TDP-43, in CA1 region. Symptomatic AD cases were considered as the reference category for comparison. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Table A23 Binary logistic regression addressing the association of Josephs’ TDP-43 pathology type α with FTD symptoms, controlled for age at death and sex. Cases with type α + β were considered as positive for type α as well as for type β, respectively. Table A24 – Binary logistic regression addressing the association of Josephs’ TDP-43 pathology type β with FTD symptoms, controlled for age at death and sex. Fields were marked with “-” when the software could not assess the statistical value due to overflow. Cases with type α + β were considered as positive for type α as well as for type β, respectively. Table A25 Binary logistic regression addressing the association of FTD symptoms with TDP + CTF pattern, controlled for age at death and sex. Only demented cases were considered. Table A26 – Binary logistic regression addressing the association of typical AD symptoms with TDP + FL pattern, controlled for age at death and sex. Only demented cases were considered.
About this article
Cite this article
Tomé, S.O., Vandenberghe, R., Ospitalieri, S. et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. acta neuropathol commun 8, 61 (2020). https://doi.org/10.1186/s40478-020-00934-5
- Alzheimer’s disease (AD)
- Frontotemporal lobar degeneration (FTLD)
- Protein aggregation